Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3478006 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Are overtly healthy male or female Japanese or non-Japanese participants, as determined by medical history and physical examination~* Women not of childbearing potential~* Are aged 18 to 55 years (20 to 55 years for Japanese participants), inclusive, at screening~Exclusion Criteria:~* Have clinically significant abnormal electrocardiogram (ECG) results~* Have persistent abnormal blood pressure or pulse rate, as determined by the investigator~* Have evidence of orthostatic hypotension, defined as a decrease in systolic or diastolic blood pressure greater than or equal to (≥)20 millimeters of mercury (mmHg) or ≥10 mmHg, respectively~* Have significant history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders~* Have a history or presence of mononeuropathy, polyneuropathy, or autonomic neuropathy~* Have significant allergies to humanized monoclonal antibodies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 10 milligram (mg) LY3478006 - Intravenous (IV) (Type: EXPERIMENTAL): Participants received single dose of 10 mg LY3478006 administered IV. Due to early termination of the study Cohort 2 to 6 (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg LY3478006 IV) were not explored for safety reasons following dosing of the first 4 participants in Cohort 1.
- Placebo - IV (Type: PLACEBO_COMPARATOR): Participants received single dose of placebo administered IV. Placebo IV Cohorts 2 through 6 were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
- 100 mg LY3478006 - Subcutaneous (SC) (Cohort 7) (Type: EXPERIMENTAL): 100 mg LY3478006 cohort 7 SC dose was not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
- Placebo - SC (Cohort 7) (Type: PLACEBO_COMPARATOR): Placebo cohort 7 SC dose were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).